Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Sintilimab plus lenvatinib as conversion therapy in patients with unresectable locally intermediate to advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase 2 study.
Authors
Lijun Wang
Beijing Cancer Hospital, Beijing, China
Lijun Wang , Hongwei Wang , Yong Cui , Kemin Jin , Wei Liu , Kun Wang , Baocai Xing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04042805
DOI
10.1200/JCO.2022.40.4_suppl.449
Abstract #
449
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.
First Author: Elena Verzoni
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study.
First Author: Tingbo Liang
Poster
2021 Gastrointestinal Cancers Symposium
Preliminary results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2020 ASCO Virtual Scientific Program
A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.
First Author: Wai Meng David Tai